CoChat

DMRT1-mediated reprogramming drives development of cancer resembling human germ cell tumors with features of totipotency

Open access

The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.

Abstract

In vivo reprogramming provokes a wide range of cell fate conversion. Here, we discover that in vivo induction of higher levels of OSKM in mouse somatic cells leads to increased expression of primordial germ cell (PGC)-related genes and provokes genome-wide erasure of genomic imprinting, which takes place exclusively in PGCs. Moreover, the in vivo OSKM reprogramming results in development of cancer that resembles human germ cell tumors. Like a subgroup of germ cell tumors, propagated tumor cells can differentiate into trophoblasts. Moreover, these tumor cells give rise to induced pluripotent stem cells (iPSCs) with expanded differentiation potential into trophoblasts. Remarkably, the tumor-derived iPSCs are able to contribute to non-neoplastic somatic cells in adult mice. Mechanistically, DMRT1, which is expressed in PGCs, drives the reprogramming and propagation of the tumor cells in vivo. Furthermore, the DMRT1-related epigenetic landscape is associated with trophoblast competence of the reprogrammed cells and provides a therapeutic target for germ cell tumors. These results reveal an unappreciated route for somatic cell reprogramming and underscore the impact of reprogramming in development of germ cell tumors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-021-25249-4

Cites

81 of 81 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Development of D-OSKM tumors that resemble human germ cell tumors. a Schematic illustration of the genomic construct of ESCs containing single- or double-OSKM polycistronic cassettes (S-/D-OSKM). b qRT-PCR analyses for expression of reprogramming factors in S-/D-OSKM MEFs at Day 3 after Dox treatment. Data are presented as means ± SD of biological triplicates. The mean expression level of S-OSKM MEFs treated with 2.0 μg/mL Dox was defined as 1 (two-way ANOVA and Tukey’s multiple-comparison test, two-sided). c Western blot analysis for each reprogramming factor in S-/D-OSKM MEFs after Dox treatment for three days. Fold increase in normalized intensity for each reprogramming factor in densitometric analysis is OCT4: 4.61, SOX2: 2.58, KLF4: 3.04, and c-MYC: 3.36. d Quantification of NANOG-positive iPSC colonies in S-/D-OSKM MEFs. Data are presented as means ± SD of three independent experiments (two-way ANOVA and Sidak’s multiple-comparison test, two-sided). e Principal component analysis (PCA) plot of gene expression profiles of mCherry-positive cells at the indicated time points in S-/D-OSKM MEFs, as determined by RNA-seq (S-/D-OSKM MEFs Day 0, n = 1; mCherry + MEFs Day 3, n = 3; Day 7, n = 3; Day 14, n = 3). f Schematic illustration of the genomic construct of D-OSKM ESCs for tissue-specific expression of OSKM in the kidney or pancreas (upper panel). The lower panel shows the protocol for Dox treatment of chimeric mice. g Representative macroscopic images of S-/D-OSKM kidney tumors. Scale bars: 5 mm. h Representative histological images and immunostaining for OCT4 and NANOG in S-/D-OSKM pancreatic tumors. Scale bars: 500 μm. i Quantification of the OCT4-positive cell area in S-/D-OSKM kidney tumors (normal kidney, n = 5; S-OSKM kidney tumor, n = 18; D-OSKM kidney tumor, n = 20). Data are presented as means ± SD of biologically independent samples (Kruskal–Wallis test and Dunn’s multiple-comparison test, two-sided). j Representative histological images and OCT4 immunostaining of splenic invasion of D-OSKM pancreatic tumor cells. Scale bars: 1000 μm. k qRT-PCR analyses for expression of pluripotency-related genes in S-/D-OSKM kidney tumors. Data are presented as means ± SD of biological triplicates. Relative expression levels to ESCs are shown (one-way ANOVA and Dunnett’s multiple-comparison test, two-sided). l Representative histological images of S-/D-OSKM tumors in the kidney and pancreas. Scale bars: 500 μm (upper) and 100 μm (lower). m Heatmap showing relative expression of uniquely upregulated genes in human testicular germ cell tumors (TGCTs) (n = 158). For identification of the uniquely upregulated genes, RNA-seq data from 23 types of human cancer were obtained from the Cancer Genome Atlas (TCGA) in the NIH GDC Data portal (https://portal.gdc.cancer.gov/) (see Fig. 7a). Uniquely upregulated genes in TGCTs were defined as genes that are expressed higher (>2 folds) in TCGTs than any other cancer type. Color range is shown using a log2 scale. n Quantification of the OCT4-positive cell area in D-OSKM kidney tumors after Dox treatment at various doses (2.0 mg/mL, n = 20; 0.4 mg/mL, n = 4; 0.25 mg/mL, n = 7; 0.13 mg/mL, n = 4). Data are presented as means ± SD of biologically independent samples (Mann–Whitney test, two-sided).
Fig. 1 Development of D-OSKM tumors that resemble human germ cell tumors. a Schematic illustration of the genomic construct of ESCs containing single- or double-OSKM polycistronic cassettes (S-/D-OSKM). b qRT-PCR analyses for expression of reprogramming factors in S-/D-OSKM MEFs at Day 3 after Dox treatment. Data are presented as means ± SD of biological triplicates. The mean expression level of S-OSKM MEFs treated with 2.0 μg/mL Dox was defined as 1 (two-way ANOVA and Tukey’s multiple-comparison test, two-sided). c Western blot analysis for each reprogramming factor in S-/D-OSKM MEFs after Dox treatment for three days. Fold increase in normalized intensity for each reprogramming factor in densitometric analysis is OCT4: 4.61, SOX2: 2.58, KLF4: 3.04, and c-MYC: 3.36. d Quantification of NANOG-positive iPSC colonies in S-/D-OSKM MEFs. Data are presented as means ± SD of three independent experiments (two-way ANOVA and Sidak’s multiple-comparison test, two-sided). e Principal component analysis (PCA) plot of gene expression profiles of mCherry-positive cells at the indicated time points in S-/D-OSKM MEFs, as determined by RNA-seq (S-/D-OSKM MEFs Day 0, n = 1; mCherry + MEFs Day 3, n = 3; Day 7, n = 3; Day 14, n = 3). f Schematic illustration of the genomic construct of D-OSKM ESCs for tissue-specific expression of OSKM in the kidney or pancreas (upper panel). The lower panel shows the protocol for Dox treatment of chimeric mice. g Representative macroscopic images of S-/D-OSKM kidney tumors. Scale bars: 5 mm. h Representative histological images and immunostaining for OCT4 and NANOG in S-/D-OSKM pancreatic tumors. Scale bars: 500 μm. i Quantification of the OCT4-positive cell area in S-/D-OSKM kidney tumors (normal kidney, n = 5; S-OSKM kidney tumor, n = 18; D-OSKM kidney tumor, n = 20). Data are presented as means ± SD of biologically independent samples (Kruskal–Wallis test and Dunn’s multiple-comparison test, two-sided). j Representative histological images and OCT4 immunostaining of splenic invasion of D-OSKM pancreatic tumor cells. Scale bars: 1000 μm. k qRT-PCR analyses for expression of pluripotency-related genes in S-/D-OSKM kidney tumors. Data are presented as means ± SD of biological triplicates. Relative expression levels to ESCs are shown (one-way ANOVA and Dunnett’s multiple-comparison test, two-sided). l Representative histological images of S-/D-OSKM tumors in the kidney and pancreas. Scale bars: 500 μm (upper) and 100 μm (lower). m Heatmap showing relative expression of uniquely upregulated genes in human testicular germ cell tumors (TGCTs) (n = 158). For identification of the uniquely upregulated genes, RNA-seq data from 23 types of human cancer were obtained from the Cancer Genome Atlas (TCGA) in the NIH GDC Data portal (https://portal.gdc.cancer.gov/) (see Fig. 7a). Uniquely upregulated genes in TGCTs were defined as genes that are expressed higher (>2 folds) in TCGTs than any other cancer type. Color range is shown using a log2 scale. n Quantification of the OCT4-positive cell area in D-OSKM kidney tumors after Dox treatment at various doses (2.0 mg/mL, n = 20; 0.4 mg/mL, n = 4; 0.25 mg/mL, n = 7; 0.13 mg/mL, n = 4). Data are presented as means ± SD of biologically independent samples (Mann–Whitney test, two-sided).CC BY · PubMed Central
Fig. 2 PGC-associated signatures in D-OSKM-induced tumors. a qRT-PCR analyses of PGC-related gene expression in S-/D-OSKM kidney tumors. Data are presented as means ± SD of biological triplicates. Relative expression levels to ESCs are shown (one-way ANOVA and Dunnett’s multiple-comparison test, two-sided). b Heatmap showing relative expression of germ line-related genes73, 74 in S-/D-OSKM kidney tumors. PGC-like cells (PGCLCs) were derived from ESCs as described previously39, 74. Color range is shown using a log2 scale. c Representative histological images and immunostaining for OCT4 and DAZL of D-OSKM kidney tumors. Scale bars: 200 μm. d Immunofluorescence staining for OCT4 and DAZL in D-OSKM kidney tumors. Scale bars: 50 μm. e DNA methylation analysis of individual CpG sites at the H19 ICR and Nespas-Gnasxl ICR in D-OSKM pancreatic tumors. f DNA methylation percentage at various genetic elements in D-OSKM pancreatic tumors, measured by whole-genome bisulfite sequencing (WGBS). CGI, CpG island; non-CGI, non-CpG island. g Heatmap showing global ICR methylation in D-OSKM pancreatic tumors, as determined by MethylC-seq analysis. n indicates the number of examined CpG sites.
Fig. 2 PGC-associated signatures in D-OSKM-induced tumors. a qRT-PCR analyses of PGC-related gene expression in S-/D-OSKM kidney tumors. Data are presented as means ± SD of biological triplicates. Relative expression levels to ESCs are shown (one-way ANOVA and Dunnett’s multiple-comparison test, two-sided). b Heatmap showing relative expression of germ line-related genes73, 74 in S-/D-OSKM kidney tumors. PGC-like cells (PGCLCs) were derived from ESCs as described previously39, 74. Color range is shown using a log2 scale. c Representative histological images and immunostaining for OCT4 and DAZL of D-OSKM kidney tumors. Scale bars: 200 μm. d Immunofluorescence staining for OCT4 and DAZL in D-OSKM kidney tumors. Scale bars: 50 μm. e DNA methylation analysis of individual CpG sites at the H19 ICR and Nespas-Gnasxl ICR in D-OSKM pancreatic tumors. f DNA methylation percentage at various genetic elements in D-OSKM pancreatic tumors, measured by whole-genome bisulfite sequencing (WGBS). CGI, CpG island; non-CGI, non-CpG island. g Heatmap showing global ICR methylation in D-OSKM pancreatic tumors, as determined by MethylC-seq analysis. n indicates the number of examined CpG sites.CC BY · PubMed Central
Fig. 3 Trophoblastic differentiation of D-OSKM tumor cells. a Representative histological images of D-OSKM pancreatic tumors containing trophoblast giant cell (TGC) clusters. Dotted lines indicate TGC clusters (>3 cells/high-power field [×400]). Scale bars: 1000 μm (left), 200 μm (right). b Incidence of tumors containing trophoblast giant cells in S-/D-OSKM chimeric mice. c Quantification of TGC cluster area in S-/D-OSKM kidney tumors (normal kidney, n = 5; S-OSKM kidney tumor, n = 16; D-OSKM kidney tumor following Dox treatment at various doses [2.0 mg/mL, n = 17; 0.4 mg/mL, n = 4; 0.25 mg/mL, n = 7; 0.13 mg/mL, n = 4]). Data are presented as means ± SD of biologically independent samples (Kruskal–Wallis test and Dunn’s multiple-comparison test, two-sided). d Representative histological images and immunostaining for CDX2 and PL-1 of D-OSKM pancreatic tumors (upper panels). Dotted lines indicate TGC clusters. Scale bars: 200 μm. Immunofluorescence staining for OCT4 and CDX2 of D-OSKM kidney tumors (lower panels). Scale bars: 50 μm. e (Left) qRT-PCR analyses of trophoblast-related gene expression in S-/D-OSKM kidney tumors. Data are presented as means ± SD of biological triplicates. Relative expression levels to TSCs are shown (one-way ANOVA and Dunnett’s multiple-comparison test, two-sided) (Right) Heatmap showing relative expression of trophoblast-related genes in S-/D-OSKM kidney tumors. Color range is shown using a log2 scale. f Lineage-tracing system for Nanog-expressing cells. Mice were treated with tamoxifen (2.0 mg) six times every other day during Dox treatment. g Immunostaining for Venus in kidney tumors (n = 4). Arrows indicate TGCs. Dotted lines indicate the TGC cluster. Scale bars: 200 μm. h Schematic illustration of an experimental protocol for in vivo D-OSKM reprogramming of somatic cells deficient for Cdx2 or Tead4. i, Representative macroscopic and histological images of Cdx2 KO and Tead4 KO D-OSKM pancreatic tumors. Scale bars: 1000 μm (middle), 500 μm (right). j Quantification of TGC cluster area in control (n = 10), Cdx2 KO (n = 4), and Tead4 KO (n = 4) D-OSKM pancreatic tumors. Data are presented as means ± SD of biologically independent samples (Kruskal–Wallis test and Dunn’s multiple-comparison test, two-sided).
Fig. 3 Trophoblastic differentiation of D-OSKM tumor cells. a Representative histological images of D-OSKM pancreatic tumors containing trophoblast giant cell (TGC) clusters. Dotted lines indicate TGC clusters (>3 cells/high-power field [×400]). Scale bars: 1000 μm (left), 200 μm (right). b Incidence of tumors containing trophoblast giant cells in S-/D-OSKM chimeric mice. c Quantification of TGC cluster area in S-/D-OSKM kidney tumors (normal kidney, n = 5; S-OSKM kidney tumor, n = 16; D-OSKM kidney tumor following Dox treatment at various doses [2.0 mg/mL, n = 17; 0.4 mg/mL, n = 4; 0.25 mg/mL, n = 7; 0.13 mg/mL, n = 4]). Data are presented as means ± SD of biologically independent samples (Kruskal–Wallis test and Dunn’s multiple-comparison test, two-sided). d Representative histological images and immunostaining for CDX2 and PL-1 of D-OSKM pancreatic tumors (upper panels). Dotted lines indicate TGC clusters. Scale bars: 200 μm. Immunofluorescence staining for OCT4 and CDX2 of D-OSKM kidney tumors (lower panels). Scale bars: 50 μm. e (Left) qRT-PCR analyses of trophoblast-related gene expression in S-/D-OSKM kidney tumors. Data are presented as means ± SD of biological triplicates. Relative expression levels to TSCs are shown (one-way ANOVA and Dunnett’s multiple-comparison test, two-sided) (Right) Heatmap showing relative expression of trophoblast-related genes in S-/D-OSKM kidney tumors. Color range is shown using a log2 scale. f Lineage-tracing system for Nanog-expressing cells. Mice were treated with tamoxifen (2.0 mg) six times every other day during Dox treatment. g Immunostaining for Venus in kidney tumors (n = 4). Arrows indicate TGCs. Dotted lines indicate the TGC cluster. Scale bars: 200 μm. h Schematic illustration of an experimental protocol for in vivo D-OSKM reprogramming of somatic cells deficient for Cdx2 or Tead4. i, Representative macroscopic and histological images of Cdx2 KO and Tead4 KO D-OSKM pancreatic tumors. Scale bars: 1000 μm (middle), 500 μm (right). j Quantification of TGC cluster area in control (n = 10), Cdx2 KO (n = 4), and Tead4 KO (n = 4) D-OSKM pancreatic tumors. Data are presented as means ± SD of biologically independent samples (Kruskal–Wallis test and Dunn’s multiple-comparison test, two-sided).CC BY · PubMed Central
Fig. 4 Derivation of D-OSKM tumor-derived PSCs with the potential to differentiate toward the extraembryonic lineage. a Schematic illustration of iPSC derivation from S-/D-OSKM kidney tumor cells (S-/D-iPSCs). A total of nine S-/D-iPSC clones were established from three independent kidney tumors. b Representative macroscopic (upper) and histological (lower) images of ESC-, S-iPSC-, and D-iPSC-derived subcutaneous tumors in immunocompromised mice (upper panels). Immunostaining for PL-1 is shown in the lower panel. Scale bars: 500 μm (left), 200 μm (middle and right). c Incidence of tumors containing TGCs (upper) and quantification of TGC cluster area in ESC (n = 9), S-iPSC (n = 21), and D-iPSC tumors (n = 33). Nine independent S-/D-iPSC clones were used. Data are presented as means ± SD (Kruskal–Wallis test and Dunn’s multiple-comparison test, two-sided). d Representative images of ESC-, S-iPSC-, and D-iPSC-derived EBs (upper panels). Lower panels show immunofluorescence staining for TFAP2C and CDX2 of D-iPSC EB at differentiation Day 8. Scale bars: 200 μm (upper), 50 μm (lower). e qRT-PCR analyses for expression of trophoblast-related genes during EB formation. Data are presented as means ± SD of biological triplicates. The mean expression level at differentiation Day 0 ESCs was defined as 1. f Representative images of blastocysts injected with GFP-labeled ESCs, S-iPSCs, or D-iPSCs. Scale bars: 20 μm. g Representative images of E13.5 chimeric concepti. The chimeric blastocysts were transferred into the uterus of pseudopregnant ICR mice. Distinct GFP signals were observed in two of 16 placentae of D-iPSC chimeric concepti (arrow). Scale bars: 5 mm. h Adult D-iPSC chimeric mouse at 10 months of age. i DNA methylation analysis of individual CpG sites at the H19 and Nespas-Gnasxl ICRs in D-iPSCs.
Fig. 4 Derivation of D-OSKM tumor-derived PSCs with the potential to differentiate toward the extraembryonic lineage. a Schematic illustration of iPSC derivation from S-/D-OSKM kidney tumor cells (S-/D-iPSCs). A total of nine S-/D-iPSC clones were established from three independent kidney tumors. b Representative macroscopic (upper) and histological (lower) images of ESC-, S-iPSC-, and D-iPSC-derived subcutaneous tumors in immunocompromised mice (upper panels). Immunostaining for PL-1 is shown in the lower panel. Scale bars: 500 μm (left), 200 μm (middle and right). c Incidence of tumors containing TGCs (upper) and quantification of TGC cluster area in ESC (n = 9), S-iPSC (n = 21), and D-iPSC tumors (n = 33). Nine independent S-/D-iPSC clones were used. Data are presented as means ± SD (Kruskal–Wallis test and Dunn’s multiple-comparison test, two-sided). d Representative images of ESC-, S-iPSC-, and D-iPSC-derived EBs (upper panels). Lower panels show immunofluorescence staining for TFAP2C and CDX2 of D-iPSC EB at differentiation Day 8. Scale bars: 200 μm (upper), 50 μm (lower). e qRT-PCR analyses for expression of trophoblast-related genes during EB formation. Data are presented as means ± SD of biological triplicates. The mean expression level at differentiation Day 0 ESCs was defined as 1. f Representative images of blastocysts injected with GFP-labeled ESCs, S-iPSCs, or D-iPSCs. Scale bars: 20 μm. g Representative images of E13.5 chimeric concepti. The chimeric blastocysts were transferred into the uterus of pseudopregnant ICR mice. Distinct GFP signals were observed in two of 16 placentae of D-iPSC chimeric concepti (arrow). Scale bars: 5 mm. h Adult D-iPSC chimeric mouse at 10 months of age. i DNA methylation analysis of individual CpG sites at the H19 and Nespas-Gnasxl ICRs in D-iPSCs.CC BY · PubMed Central
Fig. 5 Elevated DMRT1 chromatin accessibility is associated with the extended differentiation potential of PSCs. a Motif enrichment analysis of D-iPSC-specific enriched peaks in ATAC-seq (n = 270), performed using HOMER (Fisher’s exact test, two-sided). b Representative specific peaks in D-iPSCs and ATAC-qPCR analysis. Genomic regions containing DMRT1/6-binding motifs75, 76 and qPCR products are shown. Data are presented as means ± SD of biological duplicates. The mean ATAC-qPCR value of ESCs was defined as 1 (t-test, two-sided). c qRT-PCR analysis of Dmrt1 expression in ESCs, S-iPSCs, and D-iPSCs. Data are presented as means ± SD of technical triplicates. The mean expression level of ESCs was defined as 1 (one-way ANOVA, two-sided). d qRT-PCR analysis for expression of Dmrt1 in S-/D-OSKM kidney tumors. Data are presented as means ± SD of biological triplicates. Relative expression levels to ESCs are shown (one-way ANOVA and Dunnett’s multiple-comparison test, two-sided). e Representative histological images and immunostaining for OCT4, DAZL, and DMRT1 of D-OSKM kidney tumors. Scale bars: 200 μm. f Schematic illustration of the genomic construct of Dmrt1-inducible ESCs. g Representative images and immunostaining for CDX2 in Dmrt1-inducible EBs on differentiation Day 8. Scale bars: 200 μm (left), 500 μm (right). h qRT-PCR analysis of Cdx2 expression during EB differentiation. Data are presented as means ± SD of biological triplicates. The mean expression level in ESCs on differentiation Day 0 was defined as 1. i Representative histological images of tumors developed after inoculation of Dmrt1-induced cells into the testis of 6-week-old C57BL/6 N mice. Dotted lines indicate the TGC cluster. Right panel represents quantification of TGC cluster area in tumors (control, n = 6; Dmrt1-induced cells, n = 6). Data are presented as means ± SD of biologically independent samples. Scale bars: 500 μm (Mann–Whitney test, two-sided).
Fig. 5 Elevated DMRT1 chromatin accessibility is associated with the extended differentiation potential of PSCs. a Motif enrichment analysis of D-iPSC-specific enriched peaks in ATAC-seq (n = 270), performed using HOMER (Fisher’s exact test, two-sided). b Representative specific peaks in D-iPSCs and ATAC-qPCR analysis. Genomic regions containing DMRT1/6-binding motifs75, 76 and qPCR products are shown. Data are presented as means ± SD of biological duplicates. The mean ATAC-qPCR value of ESCs was defined as 1 (t-test, two-sided). c qRT-PCR analysis of Dmrt1 expression in ESCs, S-iPSCs, and D-iPSCs. Data are presented as means ± SD of technical triplicates. The mean expression level of ESCs was defined as 1 (one-way ANOVA, two-sided). d qRT-PCR analysis for expression of Dmrt1 in S-/D-OSKM kidney tumors. Data are presented as means ± SD of biological triplicates. Relative expression levels to ESCs are shown (one-way ANOVA and Dunnett’s multiple-comparison test, two-sided). e Representative histological images and immunostaining for OCT4, DAZL, and DMRT1 of D-OSKM kidney tumors. Scale bars: 200 μm. f Schematic illustration of the genomic construct of Dmrt1-inducible ESCs. g Representative images and immunostaining for CDX2 in Dmrt1-inducible EBs on differentiation Day 8. Scale bars: 200 μm (left), 500 μm (right). h qRT-PCR analysis of Cdx2 expression during EB differentiation. Data are presented as means ± SD of biological triplicates. The mean expression level in ESCs on differentiation Day 0 was defined as 1. i Representative histological images of tumors developed after inoculation of Dmrt1-induced cells into the testis of 6-week-old C57BL/6 N mice. Dotted lines indicate the TGC cluster. Right panel represents quantification of TGC cluster area in tumors (control, n = 6; Dmrt1-induced cells, n = 6). Data are presented as means ± SD of biologically independent samples. Scale bars: 500 μm (Mann–Whitney test, two-sided).CC BY · PubMed Central
Fig. 6 DMRT1 drives in vivo reprogramming and propagation of GCT-like tumor cells. a Schematic illustration of the experimental protocol for in vivo D-OSKM reprogramming of somatic cells deficient for Dmrt1. b Representative macroscopic and histological images of pancreatic tumors in Dmrt1-KO D-OSKM chimeric mice. Immunostaining for OCT4 and Ki67 in pancreatic tumors is shown in the right panels. Scale bars: 1000 μm (left), 200 μm (middle and right). c–e Quantification of tumor area (c), OCT4-positive cell area in the tumor (d), and Ki67-positive cell ratio in the OCT4-positive cell area (e) in the pancreas. D-OSKM mice that developed pancreatic tumors were evaluated in this study (control, n = 10; Dmrt1 KO18, n = 2; Dmrt1 KO21, n = 5). Data are presented as means ± SD of biologically independent samples (Mann–Whitney test, two-sided). f Immunostaining for DAZL and quantification of the DAZL-positive cell area in pancreatic tumors (control, n = 10; Dmrt1 KO18, n = 2; Dmrt1 KO21, n = 5). Data are presented as means ± SD of biologically independent samples (Mann–Whitney test, two-sided) scale bars: 200 μm. g Derivation efficiency of iPSC-like colonies from pancreatic tumors (control, n = 3; Dmrt1 KO21, n = 3). Colony counting was performed at Day 7. h Immunostaining for CDX2 and quantification of the CDX2-positive cell area in pancreatic tumors (control, n = 10; Dmrt1 KO18, n = 2; Dmrt1 KO21, n = 5). Data are presented as means ± SD of biologically independent samples (Mann–Whitney test, two-sided) scale bars: 500 μm. i qRT-PCR analyses of trophoblast-related gene expression in pancreatic tumors. Data are presented as means ± SD of biological triplicates. The mean expression level of control D-OSKM pancreatic tumors was defined as 1 (t-test, two-sided). j Schematic representation of in vivo D-OSKM reprogramming and derivation of PSCs with the expanded differentiation potential into trophoblasts.
Fig. 6 DMRT1 drives in vivo reprogramming and propagation of GCT-like tumor cells. a Schematic illustration of the experimental protocol for in vivo D-OSKM reprogramming of somatic cells deficient for Dmrt1. b Representative macroscopic and histological images of pancreatic tumors in Dmrt1-KO D-OSKM chimeric mice. Immunostaining for OCT4 and Ki67 in pancreatic tumors is shown in the right panels. Scale bars: 1000 μm (left), 200 μm (middle and right). c–e Quantification of tumor area (c), OCT4-positive cell area in the tumor (d), and Ki67-positive cell ratio in the OCT4-positive cell area (e) in the pancreas. D-OSKM mice that developed pancreatic tumors were evaluated in this study (control, n = 10; Dmrt1 KO18, n = 2; Dmrt1 KO21, n = 5). Data are presented as means ± SD of biologically independent samples (Mann–Whitney test, two-sided). f Immunostaining for DAZL and quantification of the DAZL-positive cell area in pancreatic tumors (control, n = 10; Dmrt1 KO18, n = 2; Dmrt1 KO21, n = 5). Data are presented as means ± SD of biologically independent samples (Mann–Whitney test, two-sided) scale bars: 200 μm. g Derivation efficiency of iPSC-like colonies from pancreatic tumors (control, n = 3; Dmrt1 KO21, n = 3). Colony counting was performed at Day 7. h Immunostaining for CDX2 and quantification of the CDX2-positive cell area in pancreatic tumors (control, n = 10; Dmrt1 KO18, n = 2; Dmrt1 KO21, n = 5). Data are presented as means ± SD of biologically independent samples (Mann–Whitney test, two-sided) scale bars: 500 μm. i qRT-PCR analyses of trophoblast-related gene expression in pancreatic tumors. Data are presented as means ± SD of biological triplicates. The mean expression level of control D-OSKM pancreatic tumors was defined as 1 (t-test, two-sided). j Schematic representation of in vivo D-OSKM reprogramming and derivation of PSCs with the expanded differentiation potential into trophoblasts.CC BY · PubMed Central
Fig. 7 DMRT1-mediated reprogramming provides a therapeutic target for human germ cell tumors. a Heatmap showing transcriptional correlation between human PSCs, germ-line cells, and 23 types of human cancer; analysis was performed using KeyGenes77 (AGC, male advanced germ cell; SSC, spermatogonial stem cell). RNA-seq data of ESCs, PGCs, and AGCs were obtained from GSE6339278, and those of SSCs and spermatogonia were obtained from GSE9228079. RNA-seq data from 23 types of human cancer were obtained from the Cancer Genome Atlas (TCGA) (ACC: adrenocortical carcinoma [n = 79]; BLCA: bladder urothelial carcinoma [n = 408]; BRCA: breast-invasive carcinoma [n = 1092]; CESC: cervical squamous cell carcinoma and endocervical adenocarcinoma [n = 304]; CHOL: cholangiocarcinoma [n = 36]; COAD: colon adenocarcinoma [n = 456]; ESCA: esophageal carcinoma [n = 164]; GBM: glioblastoma multiforme [n = 166]; HNSC, head and neck squamous cell carcinoma [n = 501]; KIRC: kidney renal clear-cell carcinoma [n = 530]; KIRP: kidney renal papillary cell carcinoma [n = 289]; LGG: brain lower-grade glioma [n = 512]; LIHC: liver hepatocellular carcinoma [n = 371]; LUAD: lung adenocarcinoma [n = 515]; LUSC: lung squamous cell carcinoma [n = 501]; MESO: mesothelioma [n = 86]; PCPG: pheochromocytoma and paraganglioma [n = 179]; PRAD: prostate adenocarcinoma [n = 496]; SKCM: skin cutaneous melanoma [n = 468]; STAD: stomach adenocarcinoma [n = 380]; TGCT/non-seminoma: testicular germ cell tumor/nonseminoma [n = 68]; TGCT/seminoma: testicular germ cell tumor/seminoma [n = 66]; THCA: thyroid carcinoma [n = 502]; UCEC: uterine corpus endometrial carcinoma [n = 555]). b Heatmap indicates robust Z-scores of proportions of open-chromatin regions specific to 23 types of cancer with consensus motifs for each of the indicated transcription factors (see details in “Methods” section). Transcription factors whose binding motifs are present in the highest proportions of TGCT cancer-specific open-chromatin regions are shown. Each cancer-type-specific peak set, determined by ATAC-seq, was obtained from TCGA in the NIH Genomic Data Commons portal80 (ACC, n = 9; BLCA, n = 10; BRCA, n = 74; CESC, n = 2; CHOL, n = 5; COAD, n = 38; ESCA, n = 18; GBM, n = 9; HNSC, n = 9; KIRC, n = 16; KIRP, n = 34; LGG, n = 13; LIHC, n = 17; LUAD, n = 22; LUSC, n = 16; MESO, n = 7; PCPG, n = 9; PRAD, n = 26; SKCM, n = 13; STAD, n = 21; TGCT, n = 9; THCA, n = 14; UCEC, n = 13). PanCancer represents 562,709 reproducible ATAC-seq peaks obtained from 410 tumor samples80. c Cell proliferation assay of Dmrt1-induced human GCT cell lines. Data are presented as the means ± SD of three independent experiments. d Representative images of Dmrt1-induced NCCIT at Day 5. A magnified image of a multinuclear syncytiotrophoblast-like cell is shown in the lower panel. Scale bars: 100 μm. e qRT-PCR analyses for expression of trophoblast-related genes in Dmrt1-expressing NCCIT cells. mCherry-positive Dmrt1-expressing cells were isolated using FACS. Data are presented as the means ± SD of biological triplicates. The mean expression level of Dox OFF cells was set to 1 (t-test, two-sided).
Fig. 7 DMRT1-mediated reprogramming provides a therapeutic target for human germ cell tumors. a Heatmap showing transcriptional correlation between human PSCs, germ-line cells, and 23 types of human cancer; analysis was performed using KeyGenes77 (AGC, male advanced germ cell; SSC, spermatogonial stem cell). RNA-seq data of ESCs, PGCs, and AGCs were obtained from GSE6339278, and those of SSCs and spermatogonia were obtained from GSE9228079. RNA-seq data from 23 types of human cancer were obtained from the Cancer Genome Atlas (TCGA) (ACC: adrenocortical carcinoma [n = 79]; BLCA: bladder urothelial carcinoma [n = 408]; BRCA: breast-invasive carcinoma [n = 1092]; CESC: cervical squamous cell carcinoma and endocervical adenocarcinoma [n = 304]; CHOL: cholangiocarcinoma [n = 36]; COAD: colon adenocarcinoma [n = 456]; ESCA: esophageal carcinoma [n = 164]; GBM: glioblastoma multiforme [n = 166]; HNSC, head and neck squamous cell carcinoma [n = 501]; KIRC: kidney renal clear-cell carcinoma [n = 530]; KIRP: kidney renal papillary cell carcinoma [n = 289]; LGG: brain lower-grade glioma [n = 512]; LIHC: liver hepatocellular carcinoma [n = 371]; LUAD: lung adenocarcinoma [n = 515]; LUSC: lung squamous cell carcinoma [n = 501]; MESO: mesothelioma [n = 86]; PCPG: pheochromocytoma and paraganglioma [n = 179]; PRAD: prostate adenocarcinoma [n = 496]; SKCM: skin cutaneous melanoma [n = 468]; STAD: stomach adenocarcinoma [n = 380]; TGCT/non-seminoma: testicular germ cell tumor/nonseminoma [n = 68]; TGCT/seminoma: testicular germ cell tumor/seminoma [n = 66]; THCA: thyroid carcinoma [n = 502]; UCEC: uterine corpus endometrial carcinoma [n = 555]). b Heatmap indicates robust Z-scores of proportions of open-chromatin regions specific to 23 types of cancer with consensus motifs for each of the indicated transcription factors (see details in “Methods” section). Transcription factors whose binding motifs are present in the highest proportions of TGCT cancer-specific open-chromatin regions are shown. Each cancer-type-specific peak set, determined by ATAC-seq, was obtained from TCGA in the NIH Genomic Data Commons portal80 (ACC, n = 9; BLCA, n = 10; BRCA, n = 74; CESC, n = 2; CHOL, n = 5; COAD, n = 38; ESCA, n = 18; GBM, n = 9; HNSC, n = 9; KIRC, n = 16; KIRP, n = 34; LGG, n = 13; LIHC, n = 17; LUAD, n = 22; LUSC, n = 16; MESO, n = 7; PCPG, n = 9; PRAD, n = 26; SKCM, n = 13; STAD, n = 21; TGCT, n = 9; THCA, n = 14; UCEC, n = 13). PanCancer represents 562,709 reproducible ATAC-seq peaks obtained from 410 tumor samples80. c Cell proliferation assay of Dmrt1-induced human GCT cell lines. Data are presented as the means ± SD of three independent experiments. d Representative images of Dmrt1-induced NCCIT at Day 5. A magnified image of a multinuclear syncytiotrophoblast-like cell is shown in the lower panel. Scale bars: 100 μm. e qRT-PCR analyses for expression of trophoblast-related genes in Dmrt1-expressing NCCIT cells. mCherry-positive Dmrt1-expressing cells were isolated using FACS. Data are presented as the means ± SD of biological triplicates. The mean expression level of Dox OFF cells was set to 1 (t-test, two-sided).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 81 references

Cited by

See all 51

Metadata

Authors
Taguchi, J., Shibata, H., Kabata, M., Kato, M., Fukuda, K., Tanaka, A., Ohta, S., Ukai, T., Mitsunaga, K., Yamada, Y., Nagaoka, S. I., Yamazawa, S., Ohnishi, K., Woltjen, K., Ushiku, T., Ozawa, M., Saitou, M., Shinkai, Y., Yamamoto, T., & Yamada, Y.
Affiliations
  • Institute of Medical Science, The University of Tokyo (JP)
  • Kyoto University (JP)
  • RIKEN (JP)
  • The University of Tokyo (JP)
Corresponding author
  • Yamada, Yosuke
  • Yamada, Yasuhiro
Venue
Nature Communications
Published
2021-08-19
Volume
12
Issue
1
Pages
5041-5041
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3194092796
Cited by
46
References
81
Citations by year
2026: 4 · 2025: 7 · 2024: 19 · 2023: 12 · 2022: 4
FWCI
3.14
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Kyoto University Research Information Repository (Kyoto University) (submittedVersion)
Funders
  • Naito Foundation
  • Takeda Science Foundation
  • Japan Agency for Medical Research and Development (CREST, JP19gm1110004h9903, JP18cm0106203h0003, 17jm0210039h0005)
  • Research Center Network for Realization of Regenerative Medicine
  • Ministry of Education, Culture, Sports, Science and Technology (CREST)
  • Princess Takamatsu Cancer Research Fund
  • Japan Society for the Promotion of Science (20K15801, 18H03991, 18H05530, 20H03162, 17H06098, CREST, 19H03418, 19K21352, 20H05384, 18H04026)
  • Core Research for Evolutional Science and Technology
  • Strategic International Collaborative Research Program
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Syndromes and Imprinting
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Developmental Biology and Gene Regulation
Keywords
DMRT1, OSKM, somatic cell reprogramming, germ cell tumors, primordial germ cells, induced pluripotent stem cells, trophoblast differentiation, totipotency, epigenetic reprogramming, tumor propagation, therapeutic target
MeSH terms
Animals, Cell Differentiation, Cells, Cultured, Female, Humans, Mice, Inbred ICR, Neoplasms, Neoplasms, Germ Cell and Embryonal, Transcription Factors, Genomic Imprinting, Animals, Genetically Modified, Epigenesis, Genetic, Cell Line, Tumor, Mice, Induced Pluripotent Stem Cells, Cellular Reprogramming

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: DMRT1-mediated reprogramming drives development of cancer resembling human germ cell tumors with features of totipotency. https://app.cochat.ai/papers/10.1038/s41467-021-25249-4
The paper
Taguchi, J., Shibata, H., Kabata, M., Kato, M., Fukuda, K., Tanaka, A., Ohta, S., Ukai, T., Mitsunaga, K., Yamada, Y., Nagaoka, S. I., Yamazawa, S., Ohnishi, K., Woltjen, K., Ushiku, T., Ozawa, M., Saitou, M., Shinkai, Y., Yamamoto, T., & Yamada, Y. (2021). DMRT1-mediated reprogramming drives development of cancer resembling human germ cell tumors with features of totipotency. Nature Communications. https://doi.org/10.1038/s41467-021-25249-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.